NCT00655993

Effect of Statin Therapy on C-reactive Protein Levels in Patients With Chronic Obstructive Lung Disease (COPD)

Effect of Statin Therapy on C-reactive Protein Levels in Patients With COPD

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: VA Loma Linda Health Care System · Federal
• Sex: All
• Age: 40 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

Hypothesis for this pilot study is that simvastatin will lower the levels of CRP and ET-1 in COPD patients.

Detailed description

Patients with chronic obstructive lung disease (COPD) have an ongoing systemic inflammation, which can be assessed by measuring C-reactive protein (CRP). CRP is found to be a strong and independent predictor of future COPD outcomes. Statins are a class of cholesterol lowering drugs that decrease mortality from cardiovascular disease and stroke. In addition, they have anti-inflammatory, anti-thrombotic and immunomodulatory properties. Statins lower C-reactive protein by the ability to reduce the production of interleukin (IL)-6, the cytokine that activates the acute phase CRP response. Thus the rationale for this study is to evaluate effect of statins on the levels of CRP and ET-1 in COPD patients.

Conditions

• COPD
• Inflammation

Interventions

Type	Name	Description
DRUG	simvastatin	40 mg po daily

Timeline

• Start date: 2008-04-01
• Primary completion: 2009-03-01
• Completion: 2014-08-01
• First posted: 2008-04-10
• Last updated: 2023-04-26

Locations

1 site across 1 country: United States